Pharmaceuticals
Regeneron Is Regenerating Its Uptrend
Here's how aggressive traders could play this biotech giant -- and our targets for the name.
The Final 4 Bedraggled Stocks for My 2022 Tax Loss Selling Recovery Portfolio
This quartet has had a rough 2021 but could be in for a rebound next year once investors harvest their losses in the shares.
Our Updated Strategy as AbbVie Finally Breaks Out to New Highs
The bulls are back in charge.
UnitedHealth Group's Charts Continue to Point Higher
Here's our next price target.
Karuna Therapeutics Is Doing Important Research but Its Charts Are Weak
The technical signals of the clinical-stage biotech company don't inspire confidence at this juncture.
Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
Fingers Crossed for a Small-Cap Revenge Rally in 2022
The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.
Why Are Insiders Buying These 2 Beaten Down Small-Cap Biopharmas?
Eyenovia and BioDelivery Sciences are their targets.
McCarthy Stalls, Europe's COVID Surge, Mad Love for Ford, Apple's Car Play
Plus, the headline numbers don't come close to telling the story of Thursday's action in the equity markets, which had a case of bad breadth.
Johnson & Johnson Joins the Breakup Club: Here's How to Play It
J&J will be separating into two distinct firms, but not right away.